These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11401142)

  • 21. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose phosphodiesterase inhibition improves responsiveness to inhaled nitric oxide in isolated lungs from endotoxemic rats.
    Klein A; Zils U; Bopp C; Gries A; Martin E; Gust R
    J Surg Res; 2007 Apr; 138(2):224-30. PubMed ID: 17275845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA; Lee P; Rios G; Kottke-Marchant K; Topol EJ
    Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium nitroprusside, an endothelium-derived relaxing factor congener, increases platelet cyclic GMP levels and inhibits epinephrine-exacerbated in vivo platelet thrombus formation in stenosed canine coronary arteries.
    Rovin JD; Stamler JS; Loscalzo J; Folts JD
    J Cardiovasc Pharmacol; 1993 Oct; 22(4):626-31. PubMed ID: 7505366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change.
    Jensen BO; Kleppe R; Kopperud R; Nygaard G; Døskeland SO; Holmsen H; Selheim F
    Platelets; 2011; 22(1):8-19. PubMed ID: 20958117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monophosphoryl lipid A: a novel nitric oxide-mediated therapy to attenuate platelet thrombosis?
    Przyklenk K; Hata K; Whittaker P; Elliott GT
    J Cardiovasc Pharmacol; 2000 Mar; 35(3):366-75. PubMed ID: 10710120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antithrombotic effects of BMY21190, an inhibitor of cAMP phosphodiesterase, in a canine model of coronary artery thrombosis.
    Minami M; Driscoll EM; Lucchesi BR
    Jpn Circ J; 1993 Oct; 57(10):979-92. PubMed ID: 8230679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aurintricarboxylic acid in a canine model of coronary artery thrombosis.
    Strony J; Phillips M; Brands D; Moake J; Adelman B
    Circulation; 1990 Mar; 81(3):1106-14. PubMed ID: 2306818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Komjathy SF; Poulton J; Stafford JL; Godard J
    Circulation; 1994 Jan; 89(1):361-5. PubMed ID: 8281671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs.
    Ichinose F; Adrie C; Hurford WE; Zapol WM
    J Appl Physiol (1985); 1995 Apr; 78(4):1288-95. PubMed ID: 7615435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemodynamic effects of inhaled nitric oxide and phosphodiesterase inhibitor (dipyridamole) on secondary pulmonary hypertension following heart valve surgery in adults.
    Santini F; Casali G; Franchi G; Auriemma S; Lusini M; Barozzi L; Favaro A; Messina A; Mazzucco A
    Int J Cardiol; 2005 Aug; 103(2):156-63. PubMed ID: 16080974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of cyclic flow variations and reocclusion after thrombolysis in dogs by a novel antagonist of platelet-activating factor.
    Torr SR; Haskel EJ; VonVoigtlander PF; Bergmann SR; Abendschein DR
    J Am Coll Cardiol; 1991 Dec; 18(7):1804-10. PubMed ID: 1960333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
    Wang K; Zhou X; Huang Y; Khalil M; Wiktor D; van Giezen JJ; Penn MS
    Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T; Gold HK; Leinbach RC; Yaoita H; Fallon JT; Guerrero L; Napier MA; Bunting S; Collen D
    Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.
    Mickelson JK; Simpson PJ; Cronin M; Homeister JW; Laywell E; Kitzen J; Lucchesi BR
    Circulation; 1990 Feb; 81(2):617-27. PubMed ID: 2105175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Translational therapeutics of dipyridamole.
    Kim HH; Liao JK
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):s39-42. PubMed ID: 18174451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
    Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose droperidol protects against experimental coronary thrombosis in dogs and pigs and attenuates aggregation of porcine platelets and Ca2+ mobilization in human platelets.
    Bertha BG; Sill JC; Berger I; Folts JD; Milde JH
    Anesthesiology; 1993 Apr; 78(4):733-43. PubMed ID: 8466073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
    Rebello SS; Bentley RG; Morgan SR; Kasiewski CJ; Chu V; Perrone MH; Leadley RJ
    Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide.
    al-Alaiyan S; al-Omran A; Dyer D
    Intensive Care Med; 1996 Oct; 22(10):1093-5. PubMed ID: 8923076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.